- Home
- RXRX vs APGE Comparison
RXRX vs APGE Comparison
Compare RXRX & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- APGE
- Stock Information
- Founded
- RXRX 2013
- APGE 2022
- Country
- RXRX United States
- APGE United States
- Employees
- RXRX N/A
- APGE N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RXRX Health Care
- APGE Health Care
- Exchange
- RXRX Nasdaq
- APGE Nasdaq
- Market Cap
- RXRX 2.2B
- APGE 2.4B
- IPO Year
- RXRX 2021
- APGE 2023
- Fundamental
- Price
- RXRX $4.20
- APGE $66.64
- Analyst Decision
- RXRX Buy
- APGE Strong Buy
- Analyst Count
- RXRX 4
- APGE 9
- Target Price
- RXRX $7.25
- APGE $97.33
- AVG Volume (30 Days)
- RXRX 37.2M
- APGE 730.3K
- Earning Date
- RXRX 11-05-2025
- APGE 11-10-2025
- Dividend Yield
- RXRX N/A
- APGE N/A
- EPS Growth
- RXRX N/A
- APGE N/A
- EPS
- RXRX N/A
- APGE N/A
- Revenue
- RXRX $43,689,000.00
- APGE N/A
- Revenue This Year
- RXRX $24.17
- APGE N/A
- Revenue Next Year
- RXRX $20.96
- APGE N/A
- P/E Ratio
- RXRX N/A
- APGE N/A
- Revenue Growth
- RXRX N/A
- APGE N/A
- 52 Week Low
- RXRX $3.79
- APGE $26.20
- 52 Week High
- RXRX $12.36
- APGE $67.66
- Technical
- Relative Strength Index (RSI)
- RXRX 38.50
- APGE 73.22
- Support Level
- RXRX $3.81
- APGE $61.81
- Resistance Level
- RXRX $4.37
- APGE $67.66
- Average True Range (ATR)
- RXRX 0.35
- APGE 3.73
- MACD
- RXRX -0.08
- APGE 0.19
- Stochastic Oscillator
- RXRX 24.83
- APGE 91.78
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.